A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization

Trial Profile

A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms GLAGOV; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results (n=423) of analysis characterising factors associated with ongoing disease progression in the setting of evolocumab treatment presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 29 Aug 2017 Detailed results from this trial were presented in a Late-Breaking Clinical Trials session at the European Society of Cardiology (ESC) Congress 2017, as reported in an Amgen Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top